U.S. markets close in 13 minutes
  • S&P 500

    3,823.39
    -76.72 (-1.97%)
     
  • Dow 30

    30,953.01
    -485.25 (-1.54%)
     
  • Nasdaq

    11,196.98
    -327.58 (-2.84%)
     
  • Russell 2000

    1,745.16
    -26.58 (-1.50%)
     
  • Crude Oil

    111.64
    +2.07 (+1.89%)
     
  • Gold

    1,820.60
    -4.20 (-0.23%)
     
  • Silver

    20.76
    -0.40 (-1.90%)
     
  • EUR/USD

    1.0531
    -0.0056 (-0.53%)
     
  • 10-Yr Bond

    3.2060
    +0.0120 (+0.38%)
     
  • GBP/USD

    1.2185
    -0.0085 (-0.69%)
     
  • USD/JPY

    136.1350
    +0.6890 (+0.51%)
     
  • BTC-USD

    20,315.93
    -530.07 (-2.54%)
     
  • CMC Crypto 200

    441.53
    -8.53 (-1.90%)
     
  • FTSE 100

    7,323.41
    +65.09 (+0.90%)
     
  • Nikkei 225

    27,049.47
    +178.20 (+0.66%)
     

Candel Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference

  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
Candel Therapeutics, Inc
Candel Therapeutics, Inc

NEEDHAM, Mass., May 18, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced that Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer, will present an overview of the company at H.C. Wainwright’s upcoming Annual Global Investment Conference.

Format: Pre-recorded corporate presentation
Date/Time: May 24, 2022, on-demand viewing starts at 7:00 am ET

To access the webcast recording of the company presentation, please visit the Candel Therapeutics website at https://ir.candeltx.com/news-and-events/events-and-presentations.

About Candel Therapeutics

Candel is a late clinical-stage biopharmaceutical company focused on helping patients fight cancer with oncolytic viral immunotherapies. Candel’s engineered viruses are designed to induce immunogenic cell death through direct viral-mediated cytotoxicity in cancer cells, thus releasing tumor neo-antigens while creating a pro-inflammatory microenvironment at the site of injection. Candel has established two oncolytic viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform and CAN-3110 is the lead product candidate from the HSV platform. The enLIGHTEN™ Discovery Platform is based on Candel’s HSV technology.

For more information about Candel, visit: www.candeltx.com

Forward-Looking Statements

This press release includes certain disclosures that contain “forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding the timing and advancement of development programs, include key data readout milestones; expectations regarding the therapeutic benefit of its programs; and expectations regarding cash runway and expenditures. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks and uncertainties related to the timing and advancement of development programs; expectations regarding the therapeutic benefit of the Company’s programs; the Company’s ability to efficiently discover and develop product candidates; the Company’s ability to obtain and maintain regulatory approval of product candidates; the Company’s ability to maintain its intellectual property; the implementation of the Company’s business model, and strategic plans for the Company’s business and product candidates, and other risks identified in the Company’s SEC filings, including the Company’s Registration Statement on Form S-1, the Company’s Quarterly Report on Form 10-Q filed on May 12, 2022, and subsequent filings with the SEC. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent the Company’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.

Media Contact
Heidi Chokeir, PhD
Managing Director
Canale Communications
heidi.chokeir@canalecomm.com
619-203-5391

Investor Contact
Sylvia Wheeler
Principal
Wheelhouse Life Science Advisors
swheeler@wheelhouselsa.com